| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2515 | Helenalin Acetate | Anti-inflammatory and anti-cancer agent, disrupting the cooperation of CCAAT-box/enhancer-binding protein beta (C/EBPß) and co-activator p300 |
|
| DCC2516 | Helenalin Methacrylate | Natural anti-inflammatory and anti-cancer agent |
|
| DCC2517 | Helioxanthin | Inhibitor of interleukin-1β-induced MIP-1β production |
|
| DCC2518 | Hemiasterlin | Cytotoxic peptide, inducing mitotic arrest and abnormal spindle formation |
|
| DCC2519 | Hemigossypol | The biosynthetic precursor of gossypol |
|
| DCC2520 | Hemisurfen | Heparan sulfate antagonist |
|
| DCC2521 | Heparin Disaccharide I-s Sodium Salt | Heparin derivative for treatment of thrombotic diseases |
|
| DCC2522 | Hepcidin | Master regulator of iron homeostasis, contributing to Swedish mutant APP-induced osteoclastogenesis and trabecular bone loss |
|
| DCC2523 | Hepta-histidine | Novel inhibitor of Tau aggregation against Tau-related neurodegenerative diseases including Alzheimer's disease (AD) |
|
| DCC2524 | Het-dpd-13a | Novel LsrK inhibitor (ID 50 119 μM) agaist antimicrobial resistance (AMR) |
|
| DCC2525 | Heterotaxin | Novel TGF-β Signaling Inhibitor |
|
| DCC2526 | Hetrombopag Olamine | Novel orally bioavailable, non-peptide thrombopoietin (TPO) receptor agonist |
|
| DCC2527 | Hexafluoro | Novel inhibitor of the phosphorylation of DRP1, stimulating a phenotype suggestive of respiration through mitochondrial normalization and demonstrating activity in Vemurafenib-resistant melanoma in vivo |
|
| DCC2528 | Hexim1 Inducer 4a1 | Novel potent inducer of hexamethylene bis-acetamide inducible protein 1 (HEXIM1) |
|
| DCC2529 | Hexyl-acrdim | Potent inducer of oxidative stress as well as cell cycle arrest in the S-phase, significantly decreasing intracellular ATP level |
|
| DCC2530 | Hfi-142 | Insulin-regulated aminopeptidase (IRAP) inhibitor, mprovin memory in control and memory-deficient mice models |
|
| DCC2531 | Hg-7-85-01 | Novel type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases |
|
| DCC2532 | Hgh Fragment 177-191 (tfa Salt) | Fragment 177-191 of human growth hormone, regulating fat metabolism but without the adverse effects on blood sugar or growth, stimulating lipolysis (the breakdown or destruction of fat) and inhibiting lipogenesis (the transformation of nonfat food materia |
|
| DCC2533 | Hhs-465 | Novel sulfur-triazole exchange (SuTEx) covalent probe with ~5-fold enhanced chemoselectivity for tyrosines over other nucleophilic amino acids |
|
| DCC2534 | Clomethiazole Edisylate | Positive allosteric modulator at the barbiturate/picrotoxin site of the GABAA receptor |
|
| DCC2535 | Hi-207 | Non-nucleoside reverse transcriptase inhibitor |
|
| DCC2536 | Hi-253 | Potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus (HIV) |
|
| DCC2537 | Hi-346 | Potent inhibitor of multidrug-resistant human immunodeficiency virus-1 (HIV-1) |
|
| DCC2538 | Hiapp(22-27) | Hexapeptide sequences of hIAPP, being sufficient for the formation of beta-sheet-containing amyloid fibrils and coiling around each other in a typical amyloid fibril morphology |
|
| DCC2539 | Hiapp(23-27) | Pentapeptide sequences of hIAPP, being sufficient for the formation of beta-sheet-containing amyloid fibrils and self-assemble laterally into unusually broad ribbons |
|
| DCC2540 | Hie-124 | CNS active anticonvulsant and ultra-short acting hypnotic |
|
| DCC2541 | Hif-1alpha Inhibitor-1 | Novel HIF-1alpha inhibitor |
|
| DCC2542 | Hif-1alpha-p300 Ppi Inhibitor-3 | Novel HIF-1alpha-p300 Protein Protein Interaction inhibitor |
|
| DCC2543 | Hif-hydroxylase Modulator | Novel hypoxia inducible factor hydroxylase modulator |
|
| DCC2544 | Hif-hydroxylase Modulator-ii | Novel hypoxia inducible factor hydroxylase modulator |
|
